AstraZeneca’s Tagrisso On Course To Indian Debut, Affordability Vow In Tow
Executive Summary
AstraZeneca’s lung cancer treatment appears to have made significant regulatory headway in Asia. Amid its recent record fast approval in China, Tagrisso also appears to have inched closer to potential clearance in India after a key expert panel exempted it from local trial requirements.
You may also be interested in...
Multinationals, Patients Benefit From New Approvals As China Speeds Reviews
The China FDA’s new priority reviews and faster approval procedures for innovative drugs are beginning to bear fruit, with multinationals and patients among the first beneficiaries from recent clearances from two novel cancer drugs in this large emerging market.
The BRIC/MIST Playbook: Flexibility And Sticking It Out
Innovator firms will need more than just sharp business strategies to tap into the high potential but fluid pharmaceutical markets in the BRIC/MIST countries (Brazil, Russia, India, China, Mexico, Indonesia, South Korea, and Turkey). Flexibility well beyond pricing and the ability to wait it out till the rewards creep in are vital in these markets.
Forxiga debuts in India at fraction of global prices
The Indian diabetes segment continues to buzz with action. Close on the heels of going through with a second brand plan for saxagliptin, AstraZeneca Pharma has launched Forxiga (dapaglifozin), for type 2 diabetes, on the Indian market at a fraction of international prices.